The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

Cure51 and Assistance Publique – Hôpitaux de Paris have partnered to identify biomarkers for long-term survival in pancreatic cancer.

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.

In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.

The firms are combining forces to get their cancer screening and diagnostic platforms into more hospitals in the US.

Researchers will use the funds to identify molecular signatures linked to different disease subtypes and test drugs on brain organoids.

After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.

Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.

Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.